Our group studies the role of large-scale chromosomal changes known as copy number alterations (CNA) in pancreatic ductal adenocarcinoma (PDAC). We combine state-of-the-art genomic engineering strategies with in vivo models of PDAC to uncover the mechanisms by which NACs enable cancer cells to spread and resist therapies.
We are particularly interested in the role of these alterations in immune surveillance, tumor heterogeneity and cancer genome evolution. Our long-term goal is to understand the complex biology of CNAs to identify new therapeutic strategies that target PDAC cells with these chromosomal aberrations.
Main publications in pancreatic cancer:
Barriga FM, Tsanov KM, Ho YJ, et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nature Cancer. 2022; 3(11): 1367-1385.
Alonso-Curbelo D, Ho YJ, Burdziak C, et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature. 2021; 590(7847): 642-648.
We aim to tackle pancreatic cancer dreadful reality by using in vivo and ex vivo models that faithfully recapitulate the genetic alterations commonly found in patients. In the lab, we have successfully developed and established orthotopic and metastatic syngeneic...
The Glycoimmunology Laboratory, led by Dr. Gabriel Rabinovich and currently based at the CaixaResearch Institute (Barcelona), investigates immunoregulatory circuits mediated by lectinin a wide variety of pathological contexts, including cancer, autoimmune diseases,...
Our group at IrsiCaixa focuses on the development of innovative therapeutic strategies against solid tumors, with a particular emphasis on pancreatic cancer. The group integrates immunological, molecular, and translational approaches to design and evaluate cancer...
